Overview: HHV7 Qualitative PCR TestIntroduction: The HHV7 Qualitative PCR Test detects HHV-7 DNA to diagnose infection, causing neurological symptoms or fever. Following 2023 IDSA guidelines, it uses PCR for high specificity, supporting infectious disease screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in virology for patients with suspected human herpesvirus 7 infection.
Other Names: HHV7 PCR Assay, Human Herpesvirus 7 Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: HHV-7 was identified in the 1990s. PCR-based testing improved in the 2000s, enhancing diagnostic precision for herpesvirus infections.
Purpose: Detects HHV-7 DNA to diagnose infection, guides antiviral therapy, and evaluates patients with neurological symptoms or fever.
Test Parameters: 1. HHV7 DNA
Pretest Condition: No fasting required. Collect CSF, blood, plasma, serum, or saliva at any time. Report symptoms like fever, neurological issues, or immunocompromised status.
Specimen: 1-2 mL CSF (sterile container), 2-5 mL whole blood (EDTA), 2-4 mL plasma (EDTA), 2-5 mL serum (SST), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 2 hours.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fever, neurological symptoms, or immunocompromised status (e.g., transplant, HIV). Include current medications, especially antivirals.
Consent: Written consent required, detailing the tests purpose, infection implications, and potential need for antiviral therapy.
Procedural Considerations: Uses PCR to detect HHV-7 DNA. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for immunocompromised patients.
Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Low viral load may reduce sensitivity.
Clinical Significance: Positive HHV-7 DNA confirms infection, guiding antiviral therapy. Negative results may require repeat testing or alternative viral assays.
Specialist Consultation: Consult an infectious disease specialist or neurologist for result interpretation and treatment planning.
Additional Supporting Tests: HHV-6 PCR, CMV PCR, or CSF analysis to assess viral infections.
Test Limitations: Limited to HHV-7; other herpesviruses may cause similar symptoms. Clinical correlation is needed.
References: IDSA Herpesvirus Guidelines, 2023; Journal of Virology, Clark DA, 2022.
